MannKind バランスシートの健全性
財務の健全性 基準チェック /06
MannKindの総株主資本は$-67.2M 、総負債は$319.1Mで、負債比率は-474.9%となります。総資産と総負債はそれぞれ$732.3Mと$799.5Mです。 MannKindの EBIT は$7.3Mで、利息カバレッジ比率0.2です。現金および短期投資は$111.1Mです。
主要情報
-474.85%
負債資本比率
US$319.09m
負債
| インタレスト・カバレッジ・レシオ | 0.2x |
| 現金 | US$111.13m |
| エクイティ | -US$67.20m |
| 負債合計 | US$799.50m |
| 総資産 | US$732.30m |
財務の健全性に関する最新情報
更新なし
Recent updates
ナラティブ更新 • Aug 17
MNKD: Upcoming Autoinjector Decision Will Reframe Perceived Royalty Risk
Analysts have raised their fair value estimate for MannKind from $11.00 to approximately $12.74, citing a higher Street price target of $14 that is tied to Furoscix and MNKD-201 expectations, as well as increased attention on the upcoming Furoscix ReadyFlow Autoinjector FDA decision. Analyst Commentary Recent commentary from bullish analysts on MannKind centers on rising confidence in the Furoscix franchise and the MNKD-201 program.Seeking Alpha • Aug 13
MannKind: New Approvals Majorly Increase MannKind's Prospects
Summary Three revenue streams continue to feed modest growth for MannKind. Two new FDA approvals show promise of turbocharging product growth in two of MNKD's established products. MNKD's existing liquidity should be adequate to fund its operations and launches for ~2.3 years. While I rate MNKD a " Strong Buy" based upon its FDA approvals, it still has significant risks of execution. Read the full article on Seeking Alphaナラティブ更新 • Aug 03
MNKD: Furoscix Autoinjector Approval Will Reset Perceived Royalty Risk
Analysts have lifted their price target on MannKind to $14 from $11, citing higher expectations for Furoscix and the '201 program, along with updated assumptions around tissue exposure and potential Phase 2 read-throughs. Analyst Commentary Recent research coverage around MannKind highlights growing confidence in the company’s pipeline and product execution, particularly around Furoscix and the '201 program.
ナラティブ更新 • Jun 22
MNKD: Pediatric Insulin Approval Will Test Commercial Execution And Reprice Future Upside
The latest narrative update on MannKind reflects a higher analyst price target, moving from $7.17 to $7.59, as analysts highlight Afrezza's pediatric approval while still viewing the company as a "show me" story on commercial execution. Analyst Commentary Recent research on MannKind centers on how Afrezza's pediatric approval could affect the company's long term commercial story, while mixed target moves show differing views on execution risk and valuation.ナラティブ更新 • Jun 05
MNKD: Pediatric Approval And Trial Progress Will Reset Perceived Royalty Risk
Analysts have raised their MannKind price target to $11 from $8. This reflects updated assumptions that include Afrezza's pediatric approval, a lower discount rate, and higher expected profit margins, even as projected revenue growth and future P/E move slightly lower.
ナラティブ更新 • May 21
MNKD: 2026 Pediatric Decision Will Shape Royalty Overhang And Rebound Potential
Analysts have updated their view on MannKind with a new fair value estimate of $4.75 per share, reflecting recent shifts in price targets as they balance concerns about Tyvaso DPI royalty risk against ongoing contributions from products like Furoscix and Afrezza. Analyst Commentary Recent research highlights a split in how professionals are valuing MannKind, with much of the debate centered on the durability of Tyvaso DPI royalties and how that uncertainty should be reflected in the share price.ナラティブ更新 • May 04
MNKD: Soft Mist Inhaler Risk Seen Resetting Future Royalty Upside
Narrative Update Analysts have trimmed their average price target on MannKind to about $8. This reflects updated assumptions for higher revenue growth but lower profit margins and a more moderate future P/E as they weigh potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans.ナラティブ更新 • Apr 20
MNKD: 2026 Pediatric Insulin Decision Will Reset Treprostinil Royalty Risk
Analysts have trimmed MannKind's average price target by about $0.33, reflecting slightly lower assumptions for fair value and profitability as they factor in potential long term risks to Tyvaso DPI royalties from United Therapeutics' soft mist inhaler plans, even though some still see opportunity in the broader portfolio. Analyst Commentary Recent research has become more cautious on MannKind, with several firms trimming price targets and one moving to a more neutral rating as they reassess the risk and reward around Tyvaso DPI royalties and the impact of United Therapeutics' soft mist inhaler plans.ナラティブ更新 • Apr 06
MNKD: 2026 Pediatric Decision Will Define Royalty Overhang And Bullish Setup
Narrative Update: MannKind MannKind's updated analyst price target has been reduced from about $7.50 to roughly $3.85, as analysts factor in softer modeled revenue growth, a higher discount rate, lower assumed future P/E and rising concerns that United Therapeutics' planned soft mist inhaler could weigh on the long term value of Tyvaso DPI royalties. Some still highlight potential support from Afrezza and Furoscix and argue the recent selloff may already reflect a worst case scenario.ナラティブ更新 • Mar 22
MNKD: 2026 Afrezza FDA Decisions Will Recast Treprostinil Royalty Risk
Analysts have trimmed their average price targets on MannKind by a few dollars into the mid single digit range, reflecting fresh concerns about long term Tyvaso DPI royalties as United Therapeutics pursues a soft mist inhaler, while still recognizing potential support from Furoscix and Afrezza. Analyst Commentary Recent Street commentary on MannKind highlights a split view, with many price targets pulled into a mid single digit to low double digit range as analysts weigh Tyvaso DPI royalty risk against potential contributions from Afrezza and Furoscix, as well as MannKind's broader pipeline.ナラティブ更新 • Mar 08
MNKD: 2026 FDA Decisions On Inhaled Insulin Will Reframe Royalty Risk
Analysts have trimmed their fair value view on MannKind to $7.50 from $9.61, citing lower price targets clustered around $3.50 to $11 as they factor in softer revenue growth and profit margin assumptions, as well as higher perceived risk tied to United Therapeutics' potential soft mist inhaler competition and the timing of Tyvaso DPI royalty data. Analyst Commentary Recent Street research on MannKind reflects a wide split in opinion, with some analysts focusing on potential upside from the broader product portfolio and others emphasizing new competitive risks to Tyvaso DPI royalties and collaboration revenue.ナラティブ更新 • Feb 22
MNKD: 2026 FDA Label And Pediatric Decisions Will Drive Bullish Case
Analysts have kept their fair value estimate for MannKind steady while refining key inputs like discount rate, revenue growth, profit margin and future P/E. They link their current price targets, including one at $11, to what they see as multiple potential tailwinds tied to upcoming FDA decisions on Afrezza in 2026.ナラティブ更新 • Feb 07
MNKD: Upcoming FDA Decisions In 2026 Will Define Upside Potential
Narrative Update on MannKind Analysts have trimmed their price target on MannKind from $8.00 to $7.50, balancing reduced fair value and margin assumptions with expectations for stronger revenue growth. They also recognize that recent Street research still highlights potential tailwinds tied to upcoming FDA decisions and the updated pipeline outlook.ナラティブ更新 • Jan 23
MNKD: 2026 FDA Label Decisions Will Clarify Underappreciated Upside Potential
Narrative Update on MannKind The analyst price target for MannKind has been reset to $10, reflecting updated views after one firm removed MNKD-101/NTM from its valuation while others highlight potential upside tied to upcoming FDA decisions and what they see as underappreciated tailwinds into 2026. Analyst Commentary Recent research on MannKind reflects a mix of optimism around upcoming FDA decisions and caution after the removal of MNKD-101/NTM from valuation models.ナラティブ更新 • Jan 09
MNKD: 2026 Regulatory Decisions Will Drive Reassessment Of Future Prospects
Narrative Update: MannKind Analyst Price Target Shift Analysts have reset their price targets on MannKind into a tighter US$10 to US$11 range, reflecting a mix of reduced expectations after the discontinuation of MNKD-101/NTM and continued optimism around potential 2026 tailwinds that are not yet fully reflected in the shares. Analyst Commentary Recent research views on MannKind reflect both optimism around potential 2026 catalysts and caution following pipeline changes and trial outcomes.ナラティブ更新 • Dec 23
MNKD: Future Commercial Execution Will Offset Late Stage Pipeline Disappointment
Analysts have trimmed their price target on MannKind to approximately $10 per share, a modest reduction that reflects the removal of MNKD-101/NTM from valuation assumptions, while improved revenue growth and profit margin forecasts partially offset the impact. Analyst Commentary Analyst reactions to the updated price target highlight a mixed outlook, with optimism around MannKind's core commercial performance tempered by concern over the setback in its development pipeline.ナラティブ更新 • Dec 09
MNKD: Future Commercial Portfolio Will Offset Pipeline Setback Risk
Analysts have reduced their price target on MannKind from $15.00 to $10.00 per share, citing the removal of MNKD-101/NTM from the pipeline following the discontinuation of the Phase 3 ICoN-1 trial after a futility assessment. Analyst Commentary Analysts view the updated price target as a recalibration of MannKind's valuation to reflect the loss of MNKD-101/NTM from the development pipeline, while still recognizing ongoing strengths in the core business and broader platform.ナラティブ更新 • Nov 25
MNKD: Recent Pipeline Setback Will Be Outweighed By Future Royalties Expansion
Analysts have reduced their price target for MannKind from approximately $10.06 to $9.39, citing the discontinued Phase 3 ICoN-1 trial and adjusted pipeline expectations as the main factors for the revision. Analyst Commentary Analyst sentiment on MannKind has shifted in response to recent clinical trial results, pipeline updates, and royalty projections.ナラティブ更新 • Nov 11
MNKD: Acquisition Will Drive Revenue Diversification and Support Upside Re-Rating
MannKind's fair value estimate has been revised down slightly to $10.06 per share from $10.57. Analysts are factoring in stronger revenue growth driven by TYVASO DPI royalties and the accretive acquisition of scPharmaceuticals, along with a modest change in profitability and updated discount rates.分析記事 • Sep 03
MannKind Corporation (NASDAQ:MNKD) Looks Just Right With A 53% Price Jump
MannKind Corporation ( NASDAQ:MNKD ) shareholders would be excited to see that the share price has had a great month...ナラティブ更新 • Aug 27
Pipeline Advancements And International Expansion Will Shape Future Markets
Analysts have raised MannKind’s price target to $9.71, citing the accretive acquisition of scPharmaceuticals, which expands and diversifies MannKind’s addressable market and growth prospects despite recent negative sentiment around earnings. Analyst Commentary Bullish analysts see the acquisition of scPharmaceuticals as adding a high-growth, large-market asset that diversifies MannKind's revenue base.分析記事 • May 11
Earnings Miss: MannKind Corporation Missed EPS By 5.9% And Analysts Are Revising Their Forecasts
Shareholders might have noticed that MannKind Corporation ( NASDAQ:MNKD ) filed its first-quarter result this time last...分析記事 • Mar 01
MannKind Corporation Just Missed EPS By 6.3%: Here's What Analysts Think Will Happen Next
MannKind Corporation ( NASDAQ:MNKD ) shareholders are probably feeling a little disappointed, since its shares fell...Seeking Alpha • Dec 17
MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets
Summary MannKind Corporation is a biopharmaceutical company focused on inhaled therapies for endocrine and orphan lung diseases. MNKD's revenue growth is driven by Tyvaso DPI royalties and Afrezza expansion, with pediatric trials targeting a significant underserved market. MNKD's pipeline includes MNKD-101 for nontuberculous mycobacterial lung disease and MNKD-201 for idiopathic pulmonary fibrosis, with significant market potential if successfully commercialized. The orphan lung pipeline includes MNKD-101 (Phase 3 for NTM lung disease) and MNKD-201 (Phase 1 for IPF), addressing high unmet needs. Despite high leverage, I believe MNKD's revenue growth prospects support a speculative "Buy" rating for investors seeking exposure to IPF and endocrine biotech niches. Read the full article on Seeking AlphaSeeking Alpha • Oct 03
MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion
Summary MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 million, largely due to Tyvaso DPI royalties and manufacturing income. MannKind is advancing a promising pipeline, including MNKD 101 and Nintedanib DPI, aimed at addressing unmet needs in orphan lung diseases. Financially, MannKind has strong liquidity but remains burdened by long-term debt obligations and modest net losses. I maintain a "buy" recommendation based on MannKind's solid revenue from Tyvaso DPI and its potential in expanding respiratory treatments. Read the full article on Seeking Alpha分析記事 • Sep 18
MannKind Corporation's (NASDAQ:MNKD) Share Price Boosted 28% But Its Business Prospects Need A Lift Too
Despite an already strong run, MannKind Corporation ( NASDAQ:MNKD ) shares have been powering on, with a gain of 28% in...
新しいナラティブ • Sep 12
Innovative Pipeline And Decisive Deleveraging Poise Company For Explosive Growth And Profitability
Strong demand for Tyvaso DPI and advancements in pipeline drugs like clofazimine inhalation suspension highlight MannKind's successful commercial execution and promising revenue growth prospects.分析記事 • Jul 17
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Key Insights The projected fair value for MannKind is US$11.86 based on 2 Stage Free Cash Flow to Equity MannKind is...Seeking Alpha • May 15
MannKind Outperforms As Tyvaso DPI Captures Market Share
Summary MannKind's Q1 revenue rose 63% year-over-year; net income was $10.63 million, reversing a prior loss. Tyvaso DPI, utilizing MannKind’s technosphere technology, continues to capture significant PAH market interest. Despite high current assets, the Company's long-term liabilities exceed its assets, posing potential financial risks. Recommend buying MNKD for a barbell strategy portfolio, allocating a small portion to this high-alpha stock. Read the full article on Seeking Alpha財務状況分析
短期負債: MNKDは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。
長期負債: MNKDは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。
デット・ツー・エクイティの歴史と分析
負債レベル: MNKDは 株主資本がマイナス となっており、これは高い負債レベルよりも深刻な状況です。
負債の削減: MNKDの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。
貸借対照表
キャッシュ・ランウェイ分析
過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。
安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 MNKDに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。
キャッシュランウェイの予測: MNKDの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。
健全な企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/09/21 17:54 |
| 終値 | 2026/09/18 00:00 |
| 収益 | 2026/06/30 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
MannKind Corporation 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。27
| アナリスト | 機関 |
|---|---|
| Thomas Russo | Baird |
| Stephen V. Byrne | BofA Global Research |
| null null | BTIG |